[{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"c2fb4b7e-7e4c-490d-87bd-2814f4996b26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886049","created_at":"2023-06-02T14:06:05.454Z","updated_at":"2025-02-25T13:55:14.969Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","source_id_and_acronym":"NCT05886049","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-20"},{"id":"2215a379-2b74-4e43-b073-534f2995d428","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001788","created_at":"2023-08-21T14:08:48.344Z","updated_at":"2025-02-25T15:13:42.778Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06001788","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • Komzifti (ziftomenib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-13"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"8ec351f2-1bd5-4f00-9a41-65c5a39f754f","acronym":"HTLP-ONCO","url":"https://clinicaltrials.gov/study/NCT04707300","created_at":"2021-01-19T20:51:47.092Z","updated_at":"2025-02-25T17:00:53.937Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients with Hematologic Malignancies (HTLP-ONCO)","source_id_and_acronym":"NCT04707300 - HTLP-ONCO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" HLA-DRB1 • CD34 • CD4 • CD7","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["HLA-DRB1 • CD34 • CD4 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMART 102"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/16/2022","start_date":" 02/16/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-03"},{"id":"a188d51f-518e-489f-ab1d-5187bf693db5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05918913","created_at":"2023-06-26T14:09:16.870Z","updated_at":"2025-02-25T15:45:09.016Z","phase":"","brief_title":"Expanded Access Program for Revumenib","source_id_and_acronym":"NCT05918913","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" NPM1 • NUP98","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1 • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Revuforj (revumenib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-01-10"},{"id":"ed5105cc-c09f-44e6-909c-68846cffde3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06652438","created_at":"2025-02-26T15:12:55.434Z","updated_at":"2025-02-26T15:12:55.434Z","phase":"Phase 3","brief_title":"Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML","source_id_and_acronym":"NCT06652438","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Revuforj (revumenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 415","initiation":"Initiation: 02/13/2025","start_date":" 02/13/2025","primary_txt":" Primary completion: 05/13/2028","primary_completion_date":" 05/13/2028","study_txt":" Completion: 05/31/2031","study_completion_date":" 05/31/2031","last_update_posted":"2024-10-30"},{"id":"0ab65d95-a746-4376-a36a-807e4d1f1ece","acronym":"HBO-UBC","url":"https://clinicaltrials.gov/study/NCT03739502","created_at":"2021-01-18T18:18:53.880Z","updated_at":"2025-02-25T14:15:15.599Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant","source_id_and_acronym":"NCT03739502 - HBO-UBC","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-08-19"},{"id":"3102105e-b831-48d9-b839-01e75ece3f9a","acronym":"COVALENT-103","url":"https://clinicaltrials.gov/study/NCT05918692","created_at":"2023-06-26T14:09:14.079Z","updated_at":"2024-07-02T16:35:00.712Z","phase":"Phase 1","brief_title":"A Phase 1, Study of BMF-500 in Adults With Acute Leukemia","source_id_and_acronym":"NCT05918692 - COVALENT-103","lead_sponsor":"Biomea Fusion Inc.","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • FLT3 wild-type","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMF-500"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-27"},{"id":"66017a7e-e1f3-43a3-a59a-3c773b2ee231","acronym":"AUGMENT-101","url":"https://clinicaltrials.gov/study/NCT04065399","created_at":"2021-01-18T19:55:07.775Z","updated_at":"2024-07-02T16:35:03.156Z","phase":"Phase 1/2","brief_title":"A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation","source_id_and_acronym":"NCT04065399 - AUGMENT-101","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" KMT2A • NUP98","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement","tags":["KMT2A • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Revuforj (revumenib) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-17"},{"id":"c62a7f73-b1c2-406a-b3bd-f74ccdc4bd18","acronym":"KOMET-007","url":"https://clinicaltrials.gov/study/NCT05735184","created_at":"2023-02-21T16:01:44.880Z","updated_at":"2024-07-02T16:35:03.357Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML","source_id_and_acronym":"NCT05735184 - KOMET-007","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • daunorubicin • Komzifti (ziftomenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 212","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-16"},{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"fe2e9c02-b568-4273-9f6b-89146f4af44d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756962","created_at":"2021-01-18T13:30:57.647Z","updated_at":"2024-07-02T16:35:12.037Z","phase":"Phase 2","brief_title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","source_id_and_acronym":"NCT02756962","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation","tags":["FLT3 • NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 07/06/2016","start_date":" 07/06/2016","primary_txt":" Primary completion: 07/31/2033","primary_completion_date":" 07/31/2033","study_txt":" Completion: 07/31/2033","study_completion_date":" 07/31/2033","last_update_posted":"2024-04-02"},{"id":"6920805f-47cc-46c1-9b7c-1cf720663501","acronym":"KOMET-001","url":"https://clinicaltrials.gov/study/NCT04067336","created_at":"2021-01-17T17:22:51.063Z","updated_at":"2024-07-02T16:35:14.761Z","phase":"Phase 1/2","brief_title":"First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04067336 - KOMET-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Komzifti (ziftomenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-15"},{"id":"6c05718b-8a7f-4a20-bf78-b51f8a8735e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052813","created_at":"2023-09-25T14:10:32.555Z","updated_at":"2024-07-02T16:35:18.364Z","phase":"Phase 1/2","brief_title":"A Study of BN104 in the Treatment of Acute Leukemia","source_id_and_acronym":"NCT06052813","lead_sponsor":"BioNova Pharmaceuticals (Shanghai) LTD.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/16/2023","start_date":" 09/16/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-21"},{"id":"ffb94954-f1c1-4247-b33c-267b8f6f3014","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231851","created_at":"2021-01-18T20:35:11.661Z","updated_at":"2024-07-02T16:35:20.841Z","phase":"Phase 2","brief_title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","source_id_and_acronym":"NCT04231851","lead_sponsor":"University of California, Irvine","biomarkers":" NPM1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-02-05"},{"id":"de421412-fb86-418c-a6aa-0a09654defc6","acronym":"DSP-5336-101","url":"https://clinicaltrials.gov/study/NCT04988555","created_at":"2021-08-03T18:53:07.117Z","updated_at":"2024-07-02T16:35:23.111Z","phase":"Phase 1/2","brief_title":"A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation","source_id_and_acronym":"NCT04988555 - DSP-5336-101","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" FLT3 • IDH1 • IDH2 • NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • MLL fusion","tags":["FLT3 • IDH1 • IDH2 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enzomenib (DSP-5336) • Noxafil (posaconazole)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/28/2022","start_date":" 02/28/2022","primary_txt":" Primary completion: 01/02/2025","primary_completion_date":" 01/02/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-01-18"},{"id":"1c457901-9a43-4dcc-9740-e44b1b37ea65","acronym":"NCI-2018-03465","url":"https://clinicaltrials.gov/study/NCT03862157","created_at":"2021-01-18T19:03:08.762Z","updated_at":"2024-07-02T16:35:23.829Z","phase":"Phase 1/2","brief_title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT03862157 - NCI-2018-03465","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA","pipe":" | ","alterations":" NPM1 mutation • CEBPA mutation • PDGFRA rearrangement","tags":["ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CEBPA mutation • PDGFRA rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/27/2019","start_date":" 02/27/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"55adb811-b891-4933-bcb8-86892c74e47f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04752163","created_at":"2021-02-12T13:55:51.280Z","updated_at":"2024-07-02T16:35:29.212Z","phase":"Phase 1/2","brief_title":"DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04752163","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • azacitidine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • emilumenib succinate (DS-1594) • mesna • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • Noxafil (posaconazole) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/25/2021","start_date":" 03/25/2021","primary_txt":" Primary completion: 11/08/2023","primary_completion_date":" 11/08/2023","study_txt":" Completion: 11/08/2023","study_completion_date":" 11/08/2023","last_update_posted":"2023-11-15"},{"id":"b69d0397-c02d-49d3-b488-bd1e06f73acf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04712942","created_at":"2021-01-19T20:52:51.707Z","updated_at":"2025-02-25T14:51:57.702Z","phase":"Phase 2","brief_title":"Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat","source_id_and_acronym":"NCT04712942","lead_sponsor":"University of Leipzig","biomarkers":" KIT • NPM1 • CD34","pipe":" | ","alterations":" NPM1 mutation","tags":["KIT • NPM1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • pevonedistat (MLN4924)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2023-08-21"},{"id":"ea424ad4-9fe1-4d9d-bea7-2fc6acf46bfb","acronym":"VINCENT","url":"https://clinicaltrials.gov/study/NCT05904106","created_at":"2023-06-15T18:09:01.706Z","updated_at":"2024-07-02T16:35:40.488Z","phase":"Phase 2","brief_title":"Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML","source_id_and_acronym":"NCT05904106 - VINCENT","lead_sponsor":"Technische Universität Dresden","biomarkers":" ABL1 • NPM1 • CD33","pipe":" | ","alterations":" NPM1 mutation • CD33 positive","tags":["ABL1 • NPM1 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2023-08-09"},{"id":"a4607331-5709-4874-a9ba-c8e41f606637","acronym":"AMLSG 09-09","url":"https://clinicaltrials.gov/study/NCT00893399","created_at":"2021-01-18T03:25:27.462Z","updated_at":"2024-07-02T16:35:54.662Z","phase":"Phase 3","brief_title":"Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation","source_id_and_acronym":"NCT00893399 - AMLSG 09-09","lead_sponsor":"University of Ulm","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 600","initiation":"Initiation: 05/12/2010","start_date":" 05/12/2010","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2023-02-27"},{"id":"e1c7ba24-44af-4b89-9a62-1500c297696f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02722668","created_at":"2021-01-18T13:19:16.731Z","updated_at":"2024-07-02T16:35:54.803Z","phase":"Phase 2","brief_title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","source_id_and_acronym":"NCT02722668","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2023-02-24"}]